RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Status:
Completed
Trial end date:
2020-02-27
Target enrollment:
Participant gender:
Summary
Since thyroid cancer becomes refractory to radioactive iodine, treatment options are very
limited. Tyrosine kinase inhibitors such as sorafenib have recently shown promise. This trial
seeks to expand treatment options for this disease with a new, oral drug called RAD001. It is
an inhibitor of the mTOR pathway and has shown activity in neuroendocrine cancers of the
gastrointestinal tract and has been approved for the treatment of metastatic renal cell
cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
M.D. Anderson Cancer Center Massachusetts General Hospital MOUNT SINAI HOSPITAL Mount Sinai Hospital, New York Novartis